| Literature DB >> 35544180 |
Daniel Gelman1, Ortal Yerushalmy2, Sivan Alkalay-Oren3, Chani Rakov2, Shira Ben-Porat4, Leron Khalifa2, Karen Adler3, Mohanad Abdalrhman5, Shunit Coppenhagen-Glazer2, Saima Aslam6, Robert T Schooley7, Ran Nir-Paz5, Ronen Hazan8.
Abstract
Phage therapy is a promising solution for bacterial infections that are not eradicated by conventional antibiotics. A crucial element of this approach is appropriate matching of bacteriophages and antibiotics to the bacterial target according to the clinical setting. However, there is currently little consistency in the protocols used for the laboratory evaluation of bacteriophages intended for antibacterial treatment. In this Personal View, we suggest a framework aimed to match appropriate bacteriophage-based treatments in clinical microbiology laboratories. This framework, which we have termed Clinical Phage Microbiology, is based on the current research on phage treatments. In addition, we discuss special cases that might require additional relevant evaluation, including bacteriophage interactions with the host immune response, biofilm-associated infections, and polymicrobial infections. The Clinical Phage Microbiology pipeline could serve as the basis for future standardisation of laboratory protocols for personalised phage therapy.Entities:
Mesh:
Substances:
Year: 2021 PMID: 35544180 DOI: 10.1016/S2666-5247(21)00127-0
Source DB: PubMed Journal: Lancet Microbe ISSN: 2666-5247